To investigate whether BTG2 expression is modulated by p53 in human bladder cancer cells, camptothecin (0.25–1 μmol/L) and doxorubicin (0.05–0.2 μg/mL) were applied to treat p53 wild‐type RT4 cells. The gene discussed is TP53; the disease is urinary bladder cancer.